tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tharimmune Announces $1.74M Direct Public Offering

Story Highlights
  • Tharimmune announced a $1.74 million public offering of securities on July 23, 2025.
  • Proceeds from the offering will support Tharimmune’s financial resources for future projects.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tharimmune Announces $1.74M Direct Public Offering

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Tharimmune ( (THAR) ).

On July 23, 2025, Tharimmune, Inc. announced a registered direct public offering of $1.74 million in securities, including common stock and warrants, with the offering closing on July 25, 2025. The proceeds from this offering are intended for working capital and general corporate purposes, with President Street Global, LLC acting as the exclusive placement agent. This move is expected to support Tharimmune’s strategic positioning in the biotechnology sector, enhancing its financial resources for ongoing and future projects.

The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.

More about Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates in immunology, inflammation, and oncology. The company’s lead clinical asset, TH104, is being developed for respiratory and/or nervous system depression in military personnel and chemical incident responders. Tharimmune also explores treatments for chronic pruritus in primary biliary cholangitis and autoimmune diseases, utilizing its proprietary EpiClick™ Technology for targeting solid tumors.

Average Trading Volume: 64,746

Technical Sentiment Signal: Sell

Current Market Cap: $6.29M

For an in-depth examination of THAR stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1